Webinar: Orange Book listing sheets under the microscope

Generic drug companies have recently argued that statements made in those listing sheets could be used to preclude a patent owner in proving infringement; and the courts appear to be receptive to such arguments.

Listen to our discussion on recent caselaw that could implicate your Orange Book listing strategy and learn best practices and considerations to maximize the value of your pharmaceutical patents in the United States.